

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 4, 2025

PE anti-human HLA-A2

RRID:AB_1877227

Type: Antibody

Proper Citation

(BioLegend Cat# 343306, RRID:AB_1877227)

Antibody Information

URL: http://antibodyregistry.org/AB_1877227

Proper Citation: (BioLegend Cat# 343306, RRID:AB_1877227)

Target Antigen: HLA-A2

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human HLA-A2

Description: This monoclonal targets HLA-A2

Target Organism: human

Clone ID: Clone BB7.2

Antibody ID: AB_1877227

Vendor: BioLegend

Catalog Number: 343306

Alternative Catalog Numbers: 343305

Record Creation Time: 20231110T051517+0000

Record Last Update: 20241115T055938+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human HLA-A2.

No alerts have been found for PE anti-human HLA-A2.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. *Cell reports*, 43(4), 114041.

Clutton GT, et al. (2024) CD3 downregulation identifies high-avidity human CD8 T cells. *Clinical and experimental immunology*, 215(3), 279.

Pan Y, et al. (2024) Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. *Cell reports. Medicine*, 5(6), 101590.

Hamilton I, et al. (2023) Utilizing primary HLA-G+ extravillous trophoblasts and HLA-G+ EVT-like cell lines to study maternal-fetal interactions. *STAR protocols*, 4(2), 102276.

Ferrari V, et al. (2023) Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I. *Cancer cell*, 41(10), 1717.

Herzfeldt AK, et al. (2023) Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen-specific tumor cell killing by cytotoxic T cells. *eLife*, 12.

Pettmann J, et al. (2021) The discriminatory power of the T cell receptor. *eLife*, 10.

Bagati A, et al. (2021) Integrin $\alpha 6$ -TGF β -SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. *Cancer cell*, 39(1), 54.

Melacarne A, et al. (2021) Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. *Cell reports*, 36(1), 109312.